

entre **M**éditerranéen de **M**édecine **M**oléculaire
Inserm U1065

Mechanisms of Sepsis :

From the molecular side to the patient's bedside

Laurent BOYER, DR Inserm, C3M, Nice

Inserm
La science pour la santé
From science to health



UNIVERSITÉ
CÔTE D'AZUR

Axis 1: Mechanisms of sepsis – Improving the understanding of sepsis

Coordinators: Christophe COMBADIERE, Karim ASEHNOUNE, Laurent BOYER

Contributors: Antoine DEWITTE, Catherine WERTS, Fabienne VENET, Philippe BULET, Jean-Marc CAVAILLON, Ala-eddine DEGHRANE, Fanny LANTERNIER, Marie-Elisabeth BOUGNOUX, Jessica QUINTIN, Olivier DUSSURGET, François SCHELCHER, François MEURENS, Renaud TISSIER, Djillali ANNANE.

Axis 1: Mechanisms of sepsis – Improving the understanding of sepsis

Coordinators: Christophe COMBADIERE, Karim ASEHNOUNE, Laurent BOYER

Contributors: Antoine DEWITTE, Catherine WERTS, Fabienne VENET, Philippe BULET, Jean-Marc CAVAILLON, Ala-eddine DEGHRANE, Fanny LANTERNIER, Marie-Elisabeth BOUGNOUX, Jessica QUINTIN, Olivier DUSSURGET, François SCHELCHER, François MEURENS, Renaud TISSIER, Djillali ANNANE.

Research priorities and proposition for fundings :

Infection & immunity

Microbiology of Sepsis

Nervous system & Sepsis

Organe failure and thrombosis

System biology of Sepsis

Developing new tools and models

Therapeutical targets identification

Axis 1: Mechanisms of sepsis – Improving the understanding of sepsis

Coordinators: Christophe COMBADIERE, Karim ASEHNOUNE, Laurent BOYER

Contributors: Antoine DEWITTE, Catherine WERTS, Fabienne VENET, Philippe BULET, Jean-Marc CAVAILLON, Ala-eddine DEGDMANE, Fanny LANTERNIER, Marie-Elisabeth BOUGNOUX, Jessica QUINTIN, Olivier DUSSURGET, François SCHELCHER, François MEURENS, Renaud TISSIER, Djillali ANNANE.

Research priorities and proposition for fundings :

Infection & immunity

Microbiology of Sepsis

Nervous system & Sepsis


Organe failure and thrombosis

System biology of Sepsis

Developing new tools and models

Therapeutical targets identification

CONGRATS & THANK YOU




A personal perspective:

How we bumped into exploring molecular aspects of sepsis?

The origins: Uropathogenic *Escherichia coli* infections


Trans-urethral infections in mice to determine the role of the CNF1 bacterial virulence factor



Patrick Munro

The origins: Uropathogenic *Escherichia coli* infections


Trans-uretral infections in mice to determine the role of the CNF1 bacterial virulence factor



Patrick Munro

The origins: Uropathogenic *Escherichia coli* infections

Bacteremia Model: tail vein injection in mice




Patrick Munro

What is controlling bacterial clearance during bacteremia?


What is controlling bacterial clearance during bacteremia?

This reminded us about Effector triggered immunity in drosophila


Effector-triggered immunity during drosophila systemic infection




Effector-triggered immunity during drosophila systemic infection



CNF1 toxin -triggered immunity is related to Effector triggered immunity







Does effector-triggered immunity controlling bacteremia in mice?

E. coli expressing CNF1 are cleared rapidly during bacteremia

Bacteremia Model: tail vein injection in mice




E. coli expressing CNF1 triggers an increased systemic cytokine response during bacteremia




IL-1 β signaling is essential for CNF1-triggered bacterial clearance

IL-1R signaling is required for bacterial clearance




Bacterial clearance is blocked in Caspase 1-11 KO mice




IL-1 β signaling is essential for CNF1-triggered bacterial clearance

IL-1R signaling is required for bacterial clearance




INFLAMMASOMES




Which NLR is responsible for CNF1-triggered immunity?

NLRP3 is responsible for the detection of the CNF1 toxin




⇒ RNAi screen of NLRs in macrophages




Océane Dufies

NLRP3 is essential in controlling bacterial clearance during bacteremia

NLRP3 inhibitor MCC950 inhibits the clearing of CNF1+ bacteria



NLRP3 KO mice are deficient in clearing CNF1+ bacteria




Collab V. Petrilli (CRCL, Lyon)



Océane Dufies Patrick Munro


Protective Role of NLRP3 inflammasome during bacteremia in mice




Océane Dufies Patrick Munro Raymond Ruimy Orane Visvikis Cédric Torre

NLRP3 Inflammasome :


Not always beneficial...



Abnormal activation of the NLRP3 inflammasome is implicated in many diseases




NLRP3 inflammasome activation status controls the switch from controlled bacteremia to Sepsis ?



NLPR3 inhibition protects from Sepsis in high dose infections

Bacteremia Model: tail vein injection in mice


Sepsis: 10^8 CFU/mice




Deleterious role of the NLRP3 inflammasome during Sepsis

Bacteremia Model: tail vein injection in mice

Sepsis: 10^8 CFU/mice






Should the NLRP3 inflammasome be activated or inhibited to treat bacteremic patients?

Should the NLRP3 inflammasome be activated or inhibited to treat bacteremic patients?

It is necessary to determine the activation status of NLRP3 for each bacteremic patients

Measuring inflammasome activation in the circulating leukocytes of patients with Bacteremia with or without Sepsis?



Patient's whole Blood

Immunophenotyping & Caspase-1 activation monitoring (FAM-FLICA) using flow cytometry




Johan Courjon Renaud Scussel Michel Carles

Collaboration F. Venet (HCL, Lyon) et B. Py (CIRI, Lyon)


Trial registration: [ClinicalTrials.gov NCT03869593](https://clinicaltrials.gov/ct2/show/study/NCT03869593)

Non-Classical monocytes and Eosinophils have an increased FAM-FLICA Signal during Bacteremia

Non-classical monocytes



Eosinophils




In progress, n=19/group, Sepsis= SOFA ≥ 2

Hypothesis

Non-classical monocytes

Eosinophils



Acknowledgments

C3M Team #6 MICROBIAL VIRULENCE AND INFLAMMATORY SIGNALING



C3M, Team 2
P. Auberger
A. Jacquel

C3M, Team 3
S. Marchetti
E. Verhoeven

C3M, Team 12
T. Passeron
S. Rocchi

C3M, Team 13
L. Yvan Charvet

C3M Facilities

LP2M, Nice
S. Ivanov

UGent, Belgium
M. Lamkanfi

IPBS, Toulouse
E. Meunier

CIRI, Lyon
T. Henry
B. Py

CRCL, Lyon
V. Petrilli



Thank you for your attention